Skyepharma received the notice of allowance for US patent application 13/428,548 entitled ‘Delayed Release Tablet with Defined Core Geometry’.
The US patent planned to issue will expire in 2024.
Horizon Pharma chairman, president and chief executive officer Timothy Walbert said, "This action by the USPTO is another important milestone in expanding the RAYOS patent estate and demonstrates once again our ongoing commitment, in partnership with Skyepharma, to protect the innovation and commercial potential of RAYOS."